```html

Bileaflet Mitral Valve Prolapse (BMVP)

Overview

Mitral valve prolapse (MVP) is a condition in which one or both leaflets of the mitral valve bulge (prolapse) into the left atrium during systole. Bileaflet mitral valve prolapse (BMVP) refers specifically to prolapse of *both* mitral leaflets, the most common anatomic variant of MVP.

• Who it affects: Primarily adolescents and young adults, with a slight female predominance (≈55%).
• Prevalence: MVP occurs in about 2–3 % of the general population; BMVP accounts for roughly 60–70 % of those cases [1,2].
• Nature of the condition: In most individuals BMVP is benign and asymptomatic, but in a minority it can lead to symptoms, arrhythmias, or severe valve dysfunction.

Understanding the spectrum—from silent to symptomatic disease—helps patients and clinicians decide when monitoring is enough and when intervention is required.

Symptoms

Only about 10–20 % of people with BMVP develop noticeable symptoms. The presentation can be highly variable, ranging from subtle “non‑specific” complaints to classic cardiac findings.

Typical cardiac symptoms

• Palpitations: A sensation of rapid, fluttering, or irregular heartbeats. Often triggered by anxiety, caffeine, or exercise.
• Chest discomfort: Described as sharp, stabbing, or “pressure‑like” pain; usually not related to exertion and not relieved by nitroglycerin.
• Dyspnea (shortness of breath): Especially with exertion; may be due to mild mitral regurgitation.
• Fatigue: Generalized lack of energy, often worsened after activity.
• Orthostatic intolerance: Light‑headedness or faintness when standing quickly, related to autonomic dysregulation seen in some MVP patients.

Non‑cardiac or “atypical” symptoms

• Headaches or migraine‑like episodes
• Fibromyalgia‑type musculoskeletal pain
• Gastro‑esophageal reflux–like discomfort
• Generalized anxiety or panic attacks (MVP can coexist with anxiety disorders)

Physical exam clues

• Midsystolic click: A high‑pitched sound best heard at the apex with the patient in left lateral decubitus.
• Late systolic murmur: May follow the click if significant regurgitation is present.
• Hyper‑dynamic precordium (loud heart sounds) in thin individuals.

Causes and Risk Factors

BMVP is usually a primary (idiopathic) disorder, but several genetic and environmental contributors have been identified.

Genetic factors

• Autosomal dominant inheritance with variable penetrance; families often demonstrate “floppy” valve phenotypes.
• Mutations in genes encoding extracellular matrix proteins (e.g., FBN1 for Marfan syndrome, COL3A1 for Ehlers‑Danlos) increase risk.

Associated connective‑tissue disorders

• Marfan syndrome, Loeys‑Dietz, and other collagen‑vascular diseases.
• Simple joint hypermobility (e.g., benign hypermobility syndrome).

Acquired contributors

• Rheumatic fever (rare in the U.S. but still a cause worldwide).
• Myocardial infarction or papillary‑muscle dysfunction.
• Trauma to the chest.

Risk factors for progression or complications

• Female sex (higher prevalence of symptomatic disease).
• Severe leaflet redundancy or elongation on echocardiography.
• Presence of moderate‑to‑severe mitral regurgitation at baseline.
• Co‑existing arrhythmias (e.g., atrial fibrillation, premature ventricular contractions).

Diagnosis

Diagnosis of BMVP relies on a combination of clinical assessment and imaging studies.

1. Clinical history & physical exam

Identifying the midsystolic click, murmur, and evaluating symptom patterns are the first steps.

2. Transthoracic echocardiography (TTE)

• Gold‑standard non‑invasive test.
• Shows leaflet prolapse >2 mm beyond the annular plane in both leaflets.
• Quantifies regurgitation severity (vena contracta width, regurgitant volume).

3. Transesophageal echocardiography (TEE)

Reserved for cases where TTE images are suboptimal or when surgery is being considered.

4. Cardiac magnetic resonance imaging (CMR)

• Provides detailed anatomy and can detect myocardial fibrosis, which correlates with arrhythmic risk.
• Useful in research settings and complex congenital heart disease.

5. Electrocardiogram (ECG) & Holter monitoring

• Detects arrhythmias (premature beats, atrial fibrillation, ventricular tachycardia).
• 24‑ to 48‑hour Holter is recommended for patients with palpitations or syncope.

6. Stress testing

Helps differentiate exertional dyspnea due to MVP from coronary artery disease.

Diagnostic criteria (American Society of Echocardiography, 2020)

1. Leaflet displacement ≥2 mm above the annular plane in the parasternal long‑axis view.
2. Both anterior and posterior leaflets involved (bileaflet).
3. Absence of other structural valve disease that could explain the findings.

Treatment Options

Therapy is tailored to symptom burden, degree of mitral regurgitation, and presence of arrhythmias.

1. Lifestyle & non‑pharmacologic measures

• Limit caffeine, nicotine, and other stimulants that may provoke palpitations.
• Stress‑reduction techniques (mindfulness, yoga, CBT) – particularly useful for anxiety‑related symptoms.
• Regular aerobic activity (e.g., brisk walking, swimming) is encouraged unless symptomatic with exertion.

2. Medications

• Beta‑blockers (e.g., propranolol, metoprolol): First‑line for frequent palpitations or mild chest discomfort.
• Calcium‑channel blockers (e.g., diltiazem): Alternative when beta‑blockers are contraindicated.
• Anti‑arrhythmic drugs: Flecainide or sotalol may be used for documented ventricular ectopy, but require specialist oversight.
• Anticoagulation: Indicated only if atrial fibrillation or another high‑risk thromboembolic condition develops (e.g., CHA₂DS₂‑VASc ≥2).
• ACE inhibitors/ARBs: Not routinely used for BMVP alone but may help if left ventricular dysfunction develops.

3. Interventional procedures

• Percutaneous Mitral Valve Repair (MitraClip): Considered for symptomatic severe regurgitation in patients at high surgical risk.
• Surgical mitral valve repair: Preferred over replacement when feasible; repair rates >90 % in experienced centers, with low operative mortality (≈1–2 %).
• Catheter ablation: For refractory ventricular or supraventricular arrhythmias not controlled with medication.

4. Follow‑up schedule

Patients with mild disease are typically followed every 1–2 years with TTE; those with moderate regurgitation or arrhythmias may need 6‑month intervals.

Living with Bileaflet Mitral Valve Prolapse

Daily management tips

• Track symptoms: Keep a diary of palpitations, chest pain, and activities that trigger them.
• Stay hydrated: Dehydration can exacerbate orthostatic symptoms.
• Maintain a heart‑healthy diet: Emphasize fruits, vegetables, whole grains, lean protein, and limit excess sodium.
• Exercise wisely: Warm‑up gradually; avoid extreme endurance events if you develop dyspnea or arrhythmias.
• Medication adherence: Take beta‑blockers or other drugs exactly as prescribed; never stop abruptly.
• Dental hygiene: Good oral care reduces the risk of infective endocarditis, although routine prophylaxis is no longer recommended for most MVP patients without prior endocarditis (per AHA 2023 guidelines).
• Pregnancy considerations: Most women with mild BMVP have normal pregnancies, but they should have a cardiology evaluation early to monitor for worsening regurgitation.

Psychological well‑being

Because anxiety can mimic or amplify MVP symptoms, counseling, support groups, or cognitive‑behavioral therapy can improve quality of life. The American Heart Association notes that psychosocial support reduces emergency visits in symptomatic MVP patients [3].

Prevention

While you cannot change the genetic predisposition, certain measures may reduce disease progression or symptom onset.

• Control hypertension and avoid uncontrolled blood pressure spikes.
• Maintain a normal body weight; obesity adds strain to the mitral apparatus.
• Limit alcohol intake (>2 drinks/day) which can precipitate arrhythmias.
• Screen first‑degree relatives if a family history of MVP or connective‑tissue disorder exists; early echocardiography can identify asymptomatic BMVP.

Complications

Although most patients remain uncomplicated, untreated or progressive BMVP can lead to:

• Significant mitral regurgitation: Causes left atrial enlargement, atrial fibrillation, and eventually left‑ventricular dysfunction.
• Arrhythmias: Premature ventricular contractions, non‑sustained ventricular tachycardia, or atrial fibrillation, increasing stroke risk.
• Endocarditis: Rare (<0.1 % per year) but heightened in the presence of severe regurgitation or prior infection.
• Heart failure: Usually a late manifestation when regurgitation is severe and ventricular function declines.
• Sudden cardiac death (SCD): Extremely uncommon (<0.02 % per year) but reported in patients with marked myocardial fibrosis on CMR and frequent ventricular ectopy [4].

When to Seek Emergency Care

References

1. Mayo Clinic. “Mitral valve prolapse.” Updated 2023. https://www.mayoclinic.org/…
2. American Heart Association. “Valvular Heart Disease: Mitral Valve Prolapse.” 2022. https://www.heart.org/…
3. Goldberger, A. et al. “Psychosocial factors and outcomes in mitral valve prolapse.” *J Am Coll Cardiol* 2021;78:2045‑2053.
4. Varnavas, K. et al. “Myocardial fibrosis and arrhythmic risk in bileaflet mitral valve prolapse.” *Circulation* 2022;146:165‑176.
5. U.S. Centers for Disease Control and Prevention. “Congenital Heart Defects.” 2023. https://www.cdc.gov/…
6. National Institutes of Health. “Mitral Valve Prolapse.” Genetics Home Reference. 2024. https://ghr.nlm.nih.gov/…

```